

University of Groningen

Antibody imaging as biomarker in early cancer drug development and treatment

Lamberts, Laetitia Elisabeth

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2016

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Lamberts, L. E. (2016). *Antibody imaging as biomarker in early cancer drug development and treatment*. [Thesis fully internal (DIV), University of Groningen]. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Publications

Publications

1. Janse M, **Lamberts LE**, Franke L, Raychaudhuri S, Ellinghaus E, Muri Boberg K, Melum E, Folseraas T, Schrumpf E, Bergquist A, Björnsson E, Fu J, Jan Westra H, Groen HJ, Fehrmann RS, Smolonska J, van den Berg LH, Ophoff RA, Porte RJ, Weismüller TJ, Wedemeyer J, Schramm C, Sterneck M, Günther R, Braun F, Vermeire S, Henckaerts L, Wijmenga C, Ponsioen CY, Schreiber S, Karlsen TH, Franke A, Weersma RK. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. *Hepatology* 2011; 53: 1977-85.
2. **Lamberts LE**, Janse M, Haagsma EB, van den Berg A, Weersma RK. Immune-mediated diseases in primary sclerosing cholangitis. *Digestive and Liver Disease* 2011; 43: 802-6.
3. Janse M, **Lamberts LE**, Verdonk RC, Weersma RK. IBD is associated with an increase in carcinoma in PSC irrespective of the presence of dominant bile duct stenosis. *J Hepatol* 2012; 57: 473-4.
4. Terwisscha van Scheltinga AGT, **Lamberts LE**, de Jong JR, Brouwers AH, Lub-de Hooge MN, de Vries EGE. Molecular imaging of tumors with radioactive labeled antibodies from laboratory to the clinic. *Amer Assoc Cancer Res* 2012 Education Book, p 227-232.
5. Bensch F, van Kruchten M, **Lamberts LE**, Schröder CP, Hospers GA, Brouwers AH, van Vugt MW, de Vries EG. Molecular imaging for monitoring treatment response in breast cancer patients. *Eur J Pharmacol* 2013; 717; 2-11.
6. Kol A, Terwisscha van Scheltinga AGT, Timmer-Bosscha H, **Lamberts LE**, Bensch F, de Vries EGE, Schröder CP. HER3, serious partner in crime: therapeutic approaches and potential companion diagnostics. *Pharmacology & Therapeutics* 2014; 143: 1-11.
7. Fransen K, van Sommeren S, Westra HJ, Veenstra M, **Lamberts LE**, Modderman R, Dijkstra G, Fu J, Wijmenga C, Franke L, Weersma RK, van Diemen CC. Correlation of genetic risk and messenger RNA expression in a Th17/IL23 pathway analysis in Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2014; 20: 777-82.
8. Weekes CD, **Lamberts LE**, Borad M, Voortman J, McWilliams R, Diamond J, de Vries EGE, Verheul H, Lieu C, Yue H, Wang Y, Scales SJ, Samineni D, Wood K, Brunstein F, Maslyar DJ, Kim GP. A Phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum resistant ovarian cancer (OC). *J Clin Oncol* 2014; 32: suppl; abstr 2529.
9. Gebhart G, **Lamberts LE**, Garcia C, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen W, Wimana Z, Van Dongen G, Hoekstra OS, Schröder CP, Menke- van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, De Vries EGE, Flamen P. PET/CT with ⁸⁹Zr-trastuzumab and ¹⁸F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2 positive breast cancer (mBC). *J Clin Oncol* 2014; 32: suppl; abstr 11001.

10. Bensch F, **Lamberts LE**, Lub-de Hooge MN, Terwisscha van Scheltinga AGT, De Jong JR, Gietema JA, Schröder CP, Smeenk MM, Jacob W, Abiraj K, Wolf M, Adessi C, Meneses-Lorente G, Zajac M, Weisser M, Brouwers AH, De Vries EGE. Phase I imaging study of the HER3 antibody RG7116 using ^{89}Zr -RG7116-PET in patients with metastatic or locally advanced malignant HER3-positive solid tumors. *J Clin Oncol* 2014; 32: suppl; abstr 11095.
11. **Lamberts LE**, Menke- van der Houven van Oordt CW, Voortman J, Hoekstra OS, Maslyar D, Williams SP, Fine BM, Bongaerts AHH, Gietema JA, Schröder CP, Ter Weele E, Lub-de Hooge MN, Glaudemans AWJM, Verheul HMW, Sanabria S, de Vries EGE. PET-imaging with ^{89}Zr -labeled anti-mesothelin (MSLN) antibody in patients with pancreatic cancer (PC) or ovarian cancer (OC). *Annals of Oncology* 2014; abstr 1627P.
12. **Lamberts LE**, Williams SP, Terwisscha van Scheltinga AGT, Lub-de Hooge MN, Schröder CP, Gietema JA, Brouwers AH, De Vries EGE. Antibody imaging for anticancer drug development. *J Clin Oncol* 2015; 33: 1491-504.
13. **Lamberts LE**, de Groot DJ, Bense RD, de Vries EGE, Fehrmann RS. Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types. *Oncotarget* 2015; 6: 28164-72.
14. ter Weele EJ, Terwisscha van Scheltinga AGT, Kosterink JGW, Pot L, Vedelaar SR, **Lamberts LE**, Williams SP, Lub-de Hooge MN, de Vries EGE. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ^{89}Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts. *Oncotarget* 2015; 6: 42081-90.
15. Gebhart G, **Lamberts LE**, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJG, Vugts DJ, Hoekstra OS, Schröder CP, Menke- van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EGE, Flamen P. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial. *Annals of Oncology* 2015, Epub.
16. **Lamberts LE**, Menke- van der Houven van Oordt CW, ter Weele EJ, Bensch F, Voortman J, Hoekstra OS, Williams SP, Fine BM, Maslyar D, de Jong JR, Gietema JA, Schröder CP, Bongaerts AHH, Lub-de Hooge MN, Verheul HMW, Sanabria Bohorquez SM, Glaudemans AWJM, de Vries EGE. ImmunPET with naked mesothelin antibody in pancreatic and ovarian cancer patients before anti-mesothelin antibody-drug conjugate treatment. *Clinical Cancer Research* 2015, Epub.
17. Weekes CD, **Lamberts LE**, Borad M, Voortman J, McWilliams R, Diamond JR, de Vries EGE, Verheul HMW, Lieu CH, Kim GP, Wang Y, Scales SJ, Samineni D, Brunstein F, Younjeong C, Maslyar DJ, Colon-Otero G. Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin MSLN, in patients with unresectable pancreatic or platinum resistant ovarian cancer. *Mol Cancer Ther* 2016, Epub.

